Timos Papagatsias: Interested in Social Media in the Hematology Space?
Timos Papagatsias, CEO of LucidQuest, shared on LinkedIn:
”Interested in social media in the Hematology space?
Download our ASH24 social media report!
Our team monitored and analyzed ASH-related posts on X (previously Twitter) before, during, and after the event. Here are some key takeaways:
Key Hashtags: mmsm led the discussion, emphasizing Multiple Myeloma, followed by lymsm and leusm. Hashtags like Med Twitter, mpnsm, Moffitt ASH24, MedEd, and Blood Journals also garnered significant traction, reflecting a broad and dynamic conversation around hematological research and treatment.
Top Discussion Themes: Data was the primary focus (~17.7%), highlighting the importance of evidence-based insights.
Efficacy followed closely (~16.2%), with Clinical Trials at ~13.7%. Additional themes around Treatments, patient perspectives, and Safety highlighted the drive towards more effective and patient-centered care.
Leading Voices: Doctors dominated the conversation (~56%), with Education-related and Media accounts contributing ~8% and ~10% respectively.
Research (~12%), Company (~2%), and Advocate (~10%) accounts were also active, while Nurses again scored low (~2%) in high-volume posts.
Audience Sentiment: The sentiment was overwhelmingly positive (~85%), celebrating the event’s educational value and novel insights.
About 10% were neutral, offering real-time updates and general information, while ~5% expressed negative feedback, primarily regarding session overcrowding and issues with the conference app.
Text Analytics: Discussions centered on patient-centric, data-driven approaches in Multiple Myeloma and Lymphoma management.
Treatments like CART therapy and Daratumumab attracted considerable attention, reflecting the growing impact of advanced therapeutics in hematology.
If you’re interested in social media coverage during conferences, send us a message at [email protected]; we cover multiple therapyareas and events!”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines